1,2,3-Trichloropropane

Dandiss technology CO.,LTD is a fast-growing biopharmaceutical company that engages in the research, development and manufacturing of Active Pharmaceutical Ingredients and Intermediates with primary focus on the high-end API market and late-stage drug candidates. The Company has achieved revenue growth rate of over 100% annually since its establishment in 2001. It has been rewarded research grants by the Ministry of Science and Technology for innovative breakthroughs in a number of patented pharmaceutical intermediates. Headquartered in the Center for New Medicine Discovery and Research in